Jaime R. Merchan
Experienced in Neuroendocrine Tumor

Dr. Jaime R. Merchan

Hematology Oncology | Hematology | Oncology
University Of Miami
1475 Nw 12th Ave, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Experienced in Neuroendocrine Tumor
University Of Miami
1475 Nw 12th Ave, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jaime Merchan is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Merchan is rated as an Experienced provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Adult Soft Tissue Sarcoma, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and Nephrectomy. Dr. Merchan is currently accepting new patients.

His clinical research consists of co-authoring 54 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
German
Portuguese
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UNIVERSITY OF MIAMI
1475 Nw 12th Ave, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: August 21, 2025
Intervention Type: Drug
Study Phase: Phase 1
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drugs: CPI-006 Anti-CD73 Antibody, Ciforadenant, Pembrolizumab
Study Phase: Phase 1
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: October 18, 2023
Intervention Type: Drug
Study Drug: Minnelide™Capsules
Study Phase: Phase 1
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2022
Intervention Type: Biological
Study Drugs: Pexastimogene Devacirepvec, Cemiplimab
Study Phase: Phase 1/Phase 2
Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination With Avelumab, in Patients With Refractory Solid Tumors
Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination With Avelumab, in Patients With Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: December 21, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

54 Total Publications

A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects.
A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 03, 2025
Similar Doctors
Aman Chauhan
Elite in Neuroendocrine Tumor
Dr. Aman Chauhan
Oncology
Elite in Neuroendocrine Tumor
Dr. Aman Chauhan
Oncology

University Of Miami

1611 Nw 12 Ave, 
Miami, FL 
 (0.2 miles away)
305-585-1111
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Aman Chauhan is an Oncologist in Miami, Florida. Dr. Chauhan is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Small Cell Lung Cancer (SCLC), Merkel Cell Carcinoma, Vaginectomy, and Embolectomy. Dr. Chauhan is currently accepting new patients.

Peter J. Hosein
Distinguished in Neuroendocrine Tumor
Dr. Peter J. Hosein
Hematology Oncology | Hematology | Oncology
Distinguished in Neuroendocrine Tumor
Dr. Peter J. Hosein
Hematology Oncology | Hematology | Oncology

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (0.1 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Hosein is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Hosein is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Ampullary Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Hosein is currently accepting new patients.

Distinguished in Neuroendocrine Tumor
Dr. Liat N. Dagan
Oncology | Hematology | Hematology Oncology
Distinguished in Neuroendocrine Tumor
Dr. Liat N. Dagan
Oncology | Hematology | Hematology Oncology

Brrh Oncology, LLC

800 Meadows Rd, 
Boca Raton, FL 
 (40.0 miles away)
561-955-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Liat Dagan is an Oncologist and a Hematologist in Boca Raton, Florida. Dr. Dagan is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Anemia, Chronic Lymphocytic Leukemia (CLL), Thrombocytopenia, and Chronic B-Cell Leukemia (CBCL). Dr. Dagan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Merchan's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 11 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile